慢性丙型肝炎感染的再治疗：三个中低收入国家国家治疗方案中的真实世界方案和结果。
Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.
机构信息
Clinton Health Access Initiative, Boston, Massachusetts, USA.
Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Georgia, USA.
出版信息
Clin Infect Dis. 2022 Feb 11;74(3):513-516. doi: 10.1093/cid/ciab461.
Abstract
Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well understood. Through a pooled analysis of national program data in Egypt, Georgia, and Myanmar, we observed SVR rates >90% for alternative retreatment regimens.
摘要
在中低收入国家，对于初始丙型肝炎病毒（HCV）治疗失败的患者，推荐的二线治疗方法有限。替代方案及其相关结果尚不清楚。通过对埃及、格鲁吉亚和缅甸国家项目数据的汇总分析，我们观察到替代再治疗方案的 SVR 率>90%。
相似文献
1
Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.慢性丙型肝炎感染的再治疗：三个中低收入国家国家治疗方案中的真实世界方案和结果。
Clin Infect Dis. 2022 Feb 11;74(3):513-516. doi: 10.1093/cid/ciab461.
2
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.真实世界中，对于曾对直接作用抗病毒药物（DAA）治疗失败的 HCV 患者，SOF/VEL/VOX 再治疗的结局和病毒耐药性分析。
J Viral Hepat. 2021 Sep;28(9):1256-1264. doi: 10.1111/jvh.13549. Epub 2021 Jun 8.
3
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.格鲁吉亚全国丙型肝炎消除规划中接受索磷布韦为基础联合治疗的慢性丙型肝炎患者的治疗结局。
BMC Infect Dis. 2020 Jan 10;20(1):30. doi: 10.1186/s12879-019-4741-5.
4
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.在真实世界中，对失败于 NS5A 抑制剂的 HCV 患者进行耐药指导的再治疗具有很高的疗效。
J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.
5
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.在英国感染非洲流行的丙型肝炎病毒基因型/亚型的患者中，直接作用抗病毒治疗和再治疗的真实世界结局。
J Infect Dis. 2022 Sep 21;226(6):995-1004. doi: 10.1093/infdis/jiab110.
6
Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.直接作用抗病毒药物治疗失败患者的再治疗：重点关注丙型肝炎病毒 1b 型。
World J Gastroenterol. 2017 Dec 14;23(46):8120-8127. doi: 10.3748/wjg.v23.i46.8120.
7
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.改善中低收入国家丙型肝炎治疗的可及性：患者援助计划评估。
Int J Clin Pharm. 2021 Aug;43(4):958-968. doi: 10.1007/s11096-020-01202-1. Epub 2020 Nov 28.
8
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.直接作用抗病毒治疗失败后再治疗对 HCV 基因 1-3 型感染患者的疗效。
Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6.
9
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.索磷布韦/奥贝他韦/达卡他韦/利托那韦+利巴韦林治疗丙型肝炎病毒 4 型患者的疗效。
Dig Dis Sci. 2018 May;63(5):1341-1347. doi: 10.1007/s10620-018-5005-8. Epub 2018 Mar 15.
10
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.真实生活中蛋白酶抑制剂失败后无干扰素 HCV 再治疗的最佳疗效。
Clin Microbiol Infect. 2017 Oct;23(10):777.e1-777.e4. doi: 10.1016/j.cmi.2017.04.005. Epub 2017 Apr 12.
引用本文的文献
1
Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis.8 周达卡他韦-索磷布韦方案治疗慢性丙型肝炎的疗效：系统评价和荟萃分析。
Virol J. 2024 Nov 4;21(1):275. doi: 10.1186/s12985-024-02544-2.
本文引用的文献
1
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.格卡瑞韦/哌仑他韦+索磷布韦+利巴韦林在真实世界环境中为丙型肝炎病毒再治疗提供了高治愈率。
J Hepatol. 2021 Jul;75(1):251-254. doi: 10.1016/j.jhep.2021.02.024. Epub 2021 Feb 27.
2
Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure.四联疗法为既往治疗失败的丙型肝炎病毒4型患者提供高持续病毒学应答率。
Adv Virol. 2020 Jul 24;2020:9075905. doi: 10.1155/2020/9075905. eCollection 2020.
3
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.治疗慢性丙型肝炎 1b 型和肝硬化患者，他们之前使用过包含 ombitasvir/paritaprevir/ritonavir、达沙布韦+索磷布韦+利巴韦林的直接作用抗病毒药物治疗失败，包括第一代和第二代 NS5A 抑制剂。
J Viral Hepat. 2020 May;27(5):548-551. doi: 10.1111/jvh.13254. Epub 2020 Jan 30.
4
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.用于既往治疗失败的丙型肝炎患者的新型直接作用抗病毒药物。
Clin Mol Hepatol. 2019 Dec;25(4):360-365. doi: 10.3350/cmh.2019.0022. Epub 2019 May 2.
5
Direct acting antivirals failure: cause and retreatment options.直接作用抗病毒药物失败：原因和再治疗选择。
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1245-1250. doi: 10.1080/17474124.2018.1541237. Epub 2018 Oct 31.
6
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.索磷布韦维帕他韦联合利巴韦林治疗日本基因 1 型或 2 型丙型肝炎经直接作用抗病毒药物治疗失败的患者。
Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20.
7
Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.直接作用抗病毒药物时代丙型肝炎病毒再治疗：美国的预测。
Aliment Pharmacol Ther. 2018 Apr;47(7):1023-1031. doi: 10.1111/apt.14527. Epub 2018 Jan 29.
8
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
9
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.索磷布韦-维帕他韦联合利巴韦林治疗 24 周用于既往直接作用抗病毒方案治疗的丙型肝炎病毒患者。
Hepatology. 2017 Oct;66(4):1083-1089. doi: 10.1002/hep.29256. Epub 2017 Aug 26.
10
Hepatitis C genotype 4: The past, present, and future.丙型肝炎基因4型：过去、现在与未来。
World J Hepatol. 2015 Dec 8;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792.
Zotero 插件